{"id":545883,"date":"2021-06-02T19:00:01","date_gmt":"2021-06-02T19:00:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=545883"},"modified":"2021-06-02T19:00:01","modified_gmt":"2021-06-02T19:00:01","slug":"medulloblastoma-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-oncurious-ymabs-therapeutics-senhwa-biosciences-sun-pharmaceutical-roche-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/medulloblastoma-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-oncurious-ymabs-therapeutics-senhwa-biosciences-sun-pharmaceutical-roche-and-others_545883.html","title":{"rendered":"Medulloblastoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Oncurious, Y-mAbs Therapeutics, Senhwa Biosciences, Sun Pharmaceutical, Roche and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1622609239.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Medulloblastoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Oncurious, Y-mAbs Therapeutics, Senhwa Biosciences, Sun Pharmaceutical, Roche and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1622609239.jpeg\" alt=\"Medulloblastoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Oncurious, Y-mAbs Therapeutics, Senhwa Biosciences, Sun Pharmaceutical, Roche and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Medulloblastoma Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Medulloblastoma<\/strong> is a cancerous brain tumor that starts in the lower back part of the brain, called the cerebellum. Medulloblastoma accounts for nearly 10% of all childhood brain tumors. These tumors occur exclusively in the posterior fossa and have the potential for leptomeningeal spread. Signs and symptoms of medulloblastoma may include headaches, nausea, vomiting, tiredness, dizziness, double vision, poor coordination and unsteady walk. Medulloblastoma is diagnosed based upon thorough clinical and neurological evaluation, detection of characteristic symptoms and physical findings, patient history, and specialized diagnostic tests.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/medulloblastoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Medulloblastoma Pipeline<\/a><\/strong> Insight, 2021,&rdquo; report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Medulloblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/medulloblastoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/medulloblastoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Medulloblastoma Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oncurious<\/li>\n<li>Y-mAbs Therapeutics<\/li>\n<li>Senhwa Biosciences<\/li>\n<li>Sun Pharmaceutical Industries<\/li>\n<li>Roche<\/li>\n<li>Nelum<\/li>\n<li>WPD Pharmaceuticals<\/li>\n<li>Midatech<\/li>\n<li>Kintara Therapeutics<\/li>\n<li>VBI Vaccines<\/li>\n<li>Oncoheroes Biosciences<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/medulloblastoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/medulloblastoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Medulloblastoma report covers around 12+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/medulloblastoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Medulloblastoma therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>TB-403<\/li>\n<li>Omburtamab-Lu-177<\/li>\n<li>Silmitasertib<\/li>\n<li>Sonidegib<\/li>\n<li>Vismodegib<\/li>\n<li>NLM 001<\/li>\n<li>WP1066<\/li>\n<li>Panobinostat<\/li>\n<li>Dianhydrogalactitol<\/li>\n<li>VBI 1901<\/li>\n<li>2HIT medulloblastoma<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/medulloblastoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/medulloblastoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Medulloblastoma Treatment Scenario and Medulloblastoma Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Medulloblastoma drugs?<\/li>\n<li>How many Medulloblastoma drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Medulloblastoma?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Medulloblastoma therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Medulloblastoma and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Medulloblastoma: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Medulloblastoma &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Medulloblastoma Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Drug name: Company name<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Vismodegib: Roche<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I\/II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Omburtamab-Lu-177: Y-mAbs Therapeutics<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Preclinical and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Dianhydrogalactitol: Kintara Therapeutics<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">Medulloblastoma Key Companies<\/p>\n<p style=\"text-align: justify;\">Medulloblastoma Key Products<\/p>\n<p style=\"text-align: justify;\">Medulloblastoma- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Medulloblastoma- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Medulloblastoma- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Medulloblastoma Analyst Views<\/p>\n<p style=\"text-align: justify;\">Medulloblastoma Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/medulloblastoma-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=medulloblastoma-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-oncurious-ymabs-therapeutics-senhwa-biosciences-sun-pharmaceutical-roche-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/medulloblastoma-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/medulloblastoma-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/medulloblastoma-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=medulloblastoma-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-oncurious-ymabs-therapeutics-senhwa-biosciences-sun-pharmaceutical-roche-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Medulloblastoma Pipeline Medulloblastoma is a cancerous brain tumor that starts in the lower back part of the brain, called the cerebellum. Medulloblastoma accounts for nearly 10% of all childhood brain tumors. These tumors occur exclusively in the posterior fossa and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/medulloblastoma-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-oncurious-ymabs-therapeutics-senhwa-biosciences-sun-pharmaceutical-roche-and-others_545883.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-545883","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=545883"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545883\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=545883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=545883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=545883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}